0QOI.LSE Newron Pharmaceuticals S.p.A.

Healthcare Oil, Gas & Consumable Fuels London Exchange
11.28 GBP
Close of Nov 3, 2026
6.49 31.85
Market cap
GBP 201M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 0QOI.LSE undervalued?

Graham number

The Graham number of Newron Pharmaceuticals S.p.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Newron Pharmaceuticals S.p.A. fundamental analysis

No fundamental analysis for Newron Pharmaceuticals S.p.A. yet.

Newron Pharmaceuticals S.p.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizo…

Full company profile